Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Sigilon Therapeutics history
Sigilon Therapeutics company history timeline
Douglas Cole, M.D., has served as a member of our board of directors since 2015.
Prior to Torque, Doctor Nielsen was co-founder and Chief Scientific Officer of Merrimack (NASDAQ: MACK) until 2015.
Robert R. Ruffolo, Jr., Ph.D., has served as a member of our board of directors since 2016.
Prior to launching Smith Therapeutics in 2017, Doctor Ashton-Rickardt was Chair in Immunology at Imperial College London, Visiting Professor, Brigham and Women’s Hospital, Harvard Medical School, and Associate Professor in the Department of Pathology at the University of Chicago.
Eric Shaff, M.B.A., has served as a member of our board of directors since 2017.
In 2017, he will join the faculty at Rice University as an Assistant Professor of Bioengineering.
Rogerio Vivaldi Coelho, M.D., M.B.A., has served as our President and Chief Executive Officer and as a member of our board of directors since 2018.
Prior to joining Sigilon in 2019, Doctor Harrington was the Head of Medtronic’s Biologics R&D team with a focus on developing bone regeneration therapies.
John Cox, M.B.A., has served as a member of our board of directors since 2019.
Kavita Patel, M.D., has served as a member of our board of directors since 2020.
Philip Ashton-Rickardt, Ph.D., has served as our Chief Scientific Officer since 2021.
Brooke Story, M.B.A., has served as a member of our board of directors since 2021.
Rate Sigilon Therapeutics' efforts to communicate its history to employees.
Sigilon Therapeutics jobs
Do you work at Sigilon Therapeutics?
Does Sigilon Therapeutics communicate its history to new hires?
Sigilon Therapeutics competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| SQZ Biotech | 2013 | $21.5M | 98 | - |
| Tmunity | 2015 | $5.0M | 126 | - |
| Lumos Pharma | 1999 | $2.1M | 20 | 2 |
| Hemostemix | 2006 | $284.9K | 8 | - |
| WindMIL Therapeutics | 2015 | $530,000 | 30 | - |
| Tarsa Therapeutics | 2009 | $1.6M | 10 | - |
Sigilon Therapeutics history FAQs
Zippia gives an in-depth look into the details of Sigilon Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Sigilon Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Sigilon Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Sigilon Therapeutics. The data presented on this page does not represent the view of Sigilon Therapeutics and its employees or that of Zippia.
Sigilon Therapeutics may also be known as or be related to SIGILON THERAPEUTICS, INC., Sigilon, Sigilon Therapeutics, Sigilon Therapeutics Inc and Sigilon Therapeutics, Inc.